FDA Approves sBLA for Abatacept in the Treatment of Juvenile Psoriatic Arthritis
Pharmacy Times
OCTOBER 31, 2023
The approval is supported by safety data from clinical trials assessing abatacept in the treatment of patients aged 2 to 17 with psoriatic arthritis.
Let's personalize your content